• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Final Word on SSRI for Post-Stroke Depression? Final Word on SSRI for Post-Stroke Depression?
The antidepressant fluoxetine does not prevent or alleviate post-stroke depression, new findings from a randomized, placebo-controlled trial confirm.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - August 12, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

The Efficacy and Tolerability of Selective Serotonin Reuptake Inhibitors for Motor Recovery in Non-depressed Patients After Acute Stroke: A Meta-Analysis
Conclusions: Fluoxetine and citalopram can promote motor recovery in non-depressed patients with acute stroke, but it is necessary to pay attention to the possible AEs of fluoxetine, such as hyponatremia, seizure and fracture.Systematic Review Registration: PROSPERO, identifier [CRD42021227452].
Source: Frontiers in Neurology - October 20, 2021 Category: Neurology Source Type: research

Depression Outcomes Among Patients Treated With Fluoxetine for Stroke Recovery
This randomized clinical trial investigates whether daily treatment with 20 mg of fluoxetine hydrochloride reduces the proportion of people affected by symptoms of depression after stroke.
Source: JAMA Neurology - August 2, 2021 Category: Neurology Source Type: research

Poststroke Selective Serotonin Reuptake Inhibitors
In the community, major risk factors for depression include sex, advancing age, lower income, employment status, and illnesses such as stroke that result in disability and affect income, employment, and social status. Poststroke depression affects 1 in every 3 patients in the first year after stroke occurrence and thereafter. Important general treatments for depression include the selective serotonin reuptake inhibitors; these compounds have also been suggested to modulate motor and functional recovery after stroke. The FLAME (Fluoxetine for Motor Recovery After Acute Ischaemic Stroke) trial kindled interest in treatment w...
Source: JAMA Neurology - August 2, 2021 Category: Neurology Source Type: research

Alterations of the Ceramide Metabolism in the Peri-Infarct Cortex Are Independent of the Sphingomyelinase Pathway and Not Influenced by the Acid Sphingomyelinase Inhibitor Fluoxetine.
Abstract Ceramides induce important intracellular signaling pathways, modulating proliferation, migration, apoptosis, and inflammation. However, the relevance of the ceramide metabolism in the reconvalescence phase after stroke is unclear. Besides its well-known property as a selective serotonin reuptake inhibitor, fluoxetine has been reported to inhibit the acid sphingomyelinase (ASM), a key regulator of ceramide levels which derives ceramide from sphingomyelin. Furthermore, fluoxetine has shown therapeutic potential in a randomized controlled rehabilitation trial in stroke patients. Our aim was to investigate an...
Source: Neural Plasticity - November 27, 2015 Category: Neurology Authors: Brunkhorst R, Friedlaender F, Ferreirós N, Schwalm S, Koch A, Grammatikos G, Toennes S, Foerch C, Pfeilschifter J, Pfeilschifter W Tags: Neural Plast Source Type: research

Chronic Fluoxetine Induces Activity Changes in Recovery From Poststroke Anxiety, Depression, and Cognitive Impairment
AbstractPoststroke depression (PSD) is a common outcome of stroke that limits recovery and is only partially responsive to chronic antidepressant treatment. In order to elucidate changes in the cortical-limbic circuitry associated with PSD and its treatment, we examined a novel mouse model of persistent PSD. Focal endothelin-1-induced ischemia of the left medial prefrontal cortex (mPFC) in male C57BL6 mice resulted in a chronic anxiety and depression phenotype. Here, we show severe cognitive impairment in spatial learning and memory in the stroke mice. The behavioral and cognitive phenotypes were reversed by chronic (4-wee...
Source: Neurotherapeutics - December 4, 2017 Category: Neurology Source Type: research

Fluoxetine enhances Brain Derived Neurotropic Factor Serum Concentration and Cognition in Patients with Vascular Dementia.
Abstract Selective serotonin reuptake inhibitors (SSRIs) improve cognition in patients with stroke and increase the expression of brain-derived neurotrophic factor (BDNF) in the rat hippocampus. However, the effects of SSRIs on cognition and BDNF level in vascular dementia (VaD) patients are largely unknown. We performed an open-label study to investigate the effects of fluoxetine, a selective serotonin reuptake inhibitor, on mini-mental state examination (MMSE) score and serum BDNF level in VaD patients. Fifty VaD patients were randomly allocated to receive fluoxetine (20 mg/d; n = 25) or no fluoxetine (control g...
Source: Current Neurovascular Research - August 19, 2013 Category: Neurology Authors: Liu X, Zhang J, Sun D, Fan Y, Zhou H, Fu B Tags: Curr Neurovasc Res Source Type: research

Effect of fluoxetine on HIF-1 α- Netrin/VEGF cascade, angiogenesis and neuroprotection in a rat model of transient middle cerebral artery occlusion.
Effect of fluoxetine on HIF-1α- Netrin/VEGF cascade, angiogenesis and neuroprotection in a rat model of transient middle cerebral artery occlusion. Exp Neurol. 2020 Apr 12;:113312 Authors: Hu Q, Liu L, Zhou L, Lu H, Wang J, Chen X, Wang Q Abstract Fluoxetine is one of the most promising drugs for improving clinical outcome in patients with ischemic stroke. This in vivo study investigated the hypothesis that fluoxetine may affect HIF-1α-Netrin/VEGF cascade, angiogenesis and neuroprotection using a rat model of transient middle cerebral artery occlusion (tMCAO). The rats were given fluoxetine or salin...
Source: Experimental Neurology - April 11, 2020 Category: Neurology Authors: Hu Q, Liu L, Zhou L, Lu H, Wang J, Chen X, Wang Q Tags: Exp Neurol Source Type: research

Effects of Fluoxetine on Poststroke Dysphagia: A Clinical Retrospective Study
To investigate whether fluoxetine improves poststroke dysphagia and to detect the potential relationship between serum brain-derived neurotrophic factor (BDNF) levels and fluoxetine effects.
Source: Journal of Stroke and Cerebrovascular Diseases - August 30, 2018 Category: Neurology Authors: Jianting Huang, Xuanwei Liu, Xun Luo, Chunzhi Tang, Mingzhu Xu, Lisa Wood, Yulong Wang, Qing Mei Wang Source Type: research

Fluoxetine mitigating late-stage cognition and neurobehavior impairment induced by cerebral ischemia reperfusion injury through inhibiting ERS-mediated neurons apoptosis in the hippocampus.
Abstract Existing evidence from clinical and animal experiments all indicated that fluoxetine, selective serotonin-reuptake inhibitor (SSRI) and anti-depressant drug, has neuroprotection and improve functional outcomes after stroke. Endoplasmic reticulum stress (ERS) inducing apoptosis after cerebral ischemia reperfusion injury was demonstrated in our previous. This trial was examined whether fluoxetine mitigates ERS-induced neuron apoptosis. Male sprague-dawley rats of cerebral ischemia reperfusion injury was produced via middle cerebral artery occlusion (MCAO) strategy, with ischemia for 90 min and reperfusion...
Source: Behavioural Brain Research - May 15, 2019 Category: Neurology Authors: Xu F, Zhang G, Yin J, Zhang Q, Ge MY, Peng L, Wang S, Li Y Tags: Behav Brain Res Source Type: research

Fluoxetine adjunct to therapeutic exercise promotes motor recovery in rats with cerebral ischemia: roles of nucleus accumbens.
In conclusion, the NAc may play an important role in driving physical motivation, which was possibly related to motor recovery after stroke. Fluoxetine may hasten the effectiveness of therapeutic exercise, possibly via regulating 5-HT and its receptors in the NAc. PMID: 31369829 [PubMed - as supplied by publisher]
Source: Brain Research Bulletin - July 28, 2019 Category: Neurology Authors: Hua Y, Ce L, Jian H, Wang YY, Liu PL, Gao BY, Chen C, Dong-Sheng X, Zhang B, Bai YL Tags: Brain Res Bull Source Type: research

Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial
Publication date: August 2020Source: The Lancet Neurology, Volume 19, Issue 8Author(s): Erik Lundström, Eva Isaksson, Per Näsman, Per Wester, Björn Mårtensson, Bo Norrving, Håkan Wallén, Jörgen Borg, Martin Dennis, Gillian Mead, Graeme J Hankey, Maree L Hackett, Katharina S Sunnerhagen
Source: The Lancet Neurology - July 21, 2020 Category: Neurology Source Type: research

Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial
Publication date: August 2020Source: The Lancet Neurology, Volume 19, Issue 8Author(s): Graeme J. Hankey, Maree L. Hackett, Osvaldo P. Almeida, Leon Flicker, Gillian E. Mead, Martin S. Dennis, Christopher Etherton-Beer, Andrew H. Ford, Laurent Billot, Stephen Jan, Thomas Lung, Veronica Murray, Erik Lundström, Craig S. Anderson, Robert Herbert, Gregory Carter, Geoffrey A. Donnan, Huy-Thang Nguyen, John Gommans, Qilong Yi
Source: The Lancet Neurology - July 21, 2020 Category: Neurology Source Type: research

Pages: 1  2